{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T15:12:39Z","timestamp":1766848359835,"version":"3.37.3"},"reference-count":17,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0224709","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T13:51:32Z","timestamp":1573134692000},"page":"e0224709","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Thrombocytopenia and thrombocytosis are associated with different outcome in atrial fibrillation patients on anticoagulant therapy"],"prefix":"10.1371","volume":"14","author":[{"given":"Yoav","family":"Michowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Klempfner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nir","family":"Shlomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7223-328X","authenticated-orcid":true,"given":"Maya","family":"Koren-Michowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"key":"pone.0224709.ref001","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Group ESCSD","year":"2016","journal-title":"Eur Heart J"},{"key":"pone.0224709.ref002","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","author":"CT January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"pone.0224709.ref003","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Investigators. Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"SJ Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"pone.0224709.ref004","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Investigators. Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"CB Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0224709.ref005","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"MR Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0224709.ref006","doi-asserted-by":"crossref","first-page":"781857","DOI":"10.1155\/2014\/781857","article-title":"Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis","volume":"2014","author":"K Ghoshal","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"pone.0224709.ref007","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCRESAHA.117.310795","article-title":"Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis","volume":"122","author":"M Koupenova","year":"2018","journal-title":"Circ Res"},{"key":"pone.0224709.ref008","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.hrthm.2018.08.023","article-title":"Prognostic efficacy of platelet count in patients with nonvalvular atrial fibrillation","volume":"16","author":"J Park","year":"2019","journal-title":"Heart Rhythm"},{"key":"pone.0224709.ref009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5482\/HAMO-16-06-0016","article-title":"Do we need antiplatelet therapy in thrombocytosis? Contra. Proposal for an individualized risk-adapted treatment","volume":"36","author":"RE Scharf","year":"2016","journal-title":"Hamostaseologie"},{"key":"pone.0224709.ref010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00277-016-2826-4","article-title":"Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey","volume":"96","author":"M Koren-Michowitz","year":"2017","journal-title":"Ann Hematol"},{"key":"pone.0224709.ref011","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/FJC.0000000000000607","article-title":"Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia","volume":"72","author":"A Janion-Sadowska","year":"2018","journal-title":"J Cardiovasc Pharmacol"},{"key":"pone.0224709.ref012","article-title":"Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia","author":"CL Wang","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"pone.0224709.ref013","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"AA Khorana","year":"2008","journal-title":"Blood"},{"key":"pone.0224709.ref014","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer","volume":"380","author":"M Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"pone.0224709.ref015","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ajh.24037","article-title":"New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera","volume":"90","author":"A Tefferi","year":"2015","journal-title":"Am J Hematol"},{"key":"pone.0224709.ref016","first-page":"711021","article-title":"Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials","author":"KA Hicks","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"pone.0224709.ref017","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"R Mehran","year":"2011","journal-title":"Circulation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0224709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T13:51:38Z","timestamp":1573134698000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0224709"}},"subtitle":[],"editor":[{"given":"C\u00e9cile","family":"Oury","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,11,7]]},"references-count":17,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0224709","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,11,7]]}}}